Reported 2 days ago
Citius Pharmaceuticals Inc. is preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma, targeting a release in Q2 2025. The company has completed manufacturing and established distribution agreements to ensure ample supply. A comprehensive marketing strategy is in place to support the product's introduction, leveraging GenAI models for key account engagement and developing educational resources for healthcare providers and patients. LYMPHIR's presence in clinical guidelines and reimbursement strategies positions it well for market entry.
Source: YAHOO